1873.HK

Viva Biotech Holdings [1873.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

1873.HK Stock Summary

Earnings have grown 13.1% per last year.

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Earnings are expected to fall -100% next year

1873.HK has less than 1 year of cash runway

Top 10 Correlated Stocks

1873.HK

In the News

1873.HK Financial details

Company Rating

Buy

Market Cap

1.02B

Income

-324.94M

Revenue

4.6B

Book val./share

1.9

Cash/share

0.56

Dividend

Dividend %

Employees

2.08K

Optionable

Shortable

Yes

Earnings

28 Mar 2024

P/E

-3.2

Forward P/E

PEG

0.15

P/S

0.73

P/B

0.45

P/C

0.74

P/FCF

12.68

Quick Ratio

0.25

Current Ratio

0.73

Debt / Equity

0.79

LT Debt / Equity

0.16

EPS (TTM)

-0.18

EPS next Y

EPS next Q

EPS this Y

-286.67%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

62.5%

Revenue Q/Q

-10.13%

EPS Q/Q

-100.22%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-6%

ROE

-13%

ROC

0.04%

Gross Margin

34%

Oper. Margin

Profit Margin

-21%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.455-2.0

52W High

52W Low

RSI

Rel Volume

0.71

Avg Volume

4.92M

Volume

3.5M

Perf Week

-16.16%

Perf Month

-20.19%

Perf Quarter

-67.32%

Perf Half Y

-69.71%

Beta

1.079

Volatility

0.02%, 0.04%

Prev Close

-5.68%

Price

0.415

Change

-8.79%

1873.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.19	0.22	0.45	1.1	1.26
Net income per share	0.08	0.18	-0.25	0.15	-0.28
Operating cash flow per share	0.01	0.03	0.03	0.04	0.2
Free cash flow per share	-0.03	-0.01	-0.36	-0.25	0.07
Cash per share	0.14	0.63	1.52	0.42	0.36
Book value per share	0.22	1.2	2.43	2.05	1.91
Tangible book value per share	0.22	1.2	0.93	0.64	0.52
Share holders equity per share	0.22	1.2	2.43	2.05	1.91
Interest debt per share	0.2	0.02	1.96	1.47	1.58
Market cap	4.39B	6.01B	11.93B	7.35B	2.92B
Enterprise value	4.23B	5.16B	12.59B	9.2B	5.06B
P/E ratio	48.48	22.62	-30.83	25.55	-5.52
Price to sales ratio	20.9	18.62	17.12	3.49	1.23
POCF ratio	362.51	130.71	276.24	94.41	7.56
PFCF ratio	-126.18	-591	-21.71	-15.08	21.33
P/B Ratio	17.46	3.38	3.18	1.88	0.81
PTB ratio	17.46	3.38	3.18	1.88	0.81
EV to sales	20.16	15.97	18.06	4.37	2.13
Enterprise value over EBITDA	70.41	72.89	76.6	24.87	11.6
EV to operating cash flow	349.67	112.13	291.55	118.23	13.11
EV to free cash flow	-121.7	-507.01	-22.91	-18.88	37.02
Earnings yield	0.02	0.04	-0.03	0.04	-0.18
Free cash flow yield	-0.01	0	-0.05	-0.07	0.05
Debt to equity	0.88	0.01	0.79	0.67	0.78
Debt to assets	0.42	0.01	0.36	0.33	0.35
Net debt to EBITDA	-2.59	-12.07	4.02	5.01	4.91
Current ratio	5.68	15	4.56	2.14	0.73
Interest coverage	0	24.03	1.81	1.29	1.44
Income quality	0.13	0.17	-0.11	0.27	-0.73
Dividend Yield	0	0	0	0	0
Payout ratio	0	0.06	-0.13	0.06	0
Sales general and administrative to revenue	0.12	0.16	0.16	0.11	0.11
Research and developement to revenue	0.12	0.14	0.09	0.04	0.06
Intangibles to total assets	0	0.41	0.28	0.33	0.33
Capex to operating cash flow	-3.87	-1.22	-13.72	-7.26	-0.65
Capex to revenue	-0.22	-0.17	-0.85	-0.27	-0.1
Capex to depreciation	-4.91	-1.65	-8.44	-3.69	-1.34
Stock based compensation to revenue	0.04	0.03	0.02	0.01	0.01
Graham number	0.63	2.21	3.7	2.63	3.47
ROIC	0.09	0.03	0.02	0.03	0.05
Return on tangible assets	0.17	0.24	-0.07	0.05	-0.1
Graham Net	-0.07	0.58	-1.11	-1.51	-1.66
Working capital	198.71M	1.02B	2.62B	1.06B	-733.75M
Tangible asset value	251.44M	997.12M	1.44B	1.23B	972.23M
Net current asset value	-36.73M	973.04M	-1.05B	-2.15B	-2.38B
Invested capital	0.88	0.01	0.79	0.67	0.78
Average receivables	40.05M	54.48M	189.01M	375.11M	437.84M
Average payables	4.23M	6.12M	151.63M	288.38M	303.59M
Average inventory	4.11M	6.72M	86.64M	198.23M	278.88M
Days sales outstanding	89.43	64.97	167.85	74.54	68.41
Days payables outstanding	16.35	16.49	275.27	70.6	76.11
Days of inventory on hand	17.1	18.62	153.36	58.21	76.09
Receivables turnover	4.08	5.62	2.17	4.9	5.34
Payables turnover	22.32	22.14	1.33	5.17	4.8
Inventory turnover	21.34	19.6	2.38	6.27	4.8
ROE	0.36	0.15	-0.1	0.07	-0.15
Capex per share	-0.04	-0.04	-0.38	-0.3	-0.13

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2021-12-31	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.54	0.56	0.61	0.66	0.6
Net income per share	0.04	0.11	-0.05	-0.23	0
Operating cash flow per share	0.01	0.03	0.05	0.15	0.17
Free cash flow per share	-0.11	-0.15	-0.02	0.09	0.11
Cash per share	0.53	0.42	0.39	0.35	0.56
Book value per share	1.98	2.04	2.17	1.88	1.9
Tangible book value per share	0.56	0.64	0.7	0.51	0.54
Share holders equity per share	1.98	2.04	2.17	1.88	1.9
Interest debt per share	1.23	1.37	1.54	1.46	1.5
Market cap	15.84B	7.36B	4.2B	2.96B	2.66B
Enterprise value	17.55B	9.22B	6.3B	5.1B	4.49B
P/E ratio	46.59	9.09	-11.51	-1.69	656.33
Price to sales ratio	15.44	6.83	3.79	2.33	2.33
POCF ratio	875.1	123.28	45.35	10.09	8.38
PFCF ratio	-78.31	-25.83	-95.33	16.37	12.32
P/B Ratio	4.18	1.88	1.07	0.82	0.73
PTB ratio	4.18	1.88	1.07	0.82	0.73
EV to sales	17.1	8.55	5.68	4.02	3.93
Enterprise value over EBITDA	84.56	56.77	34.18	20.25	19.68
EV to operating cash flow	969.54	154.32	68	17.39	14.15
EV to free cash flow	-86.76	-32.34	-142.93	28.23	20.8
Earnings yield	0.01	0.03	-0.02	-0.15	0
Free cash flow yield	-0.01	-0.04	-0.01	0.06	0.08
Debt to equity	0.62	0.67	0.71	0.78	0.79
Debt to assets	0.3	0.33	0.34	0.35	0.35
Net debt to EBITDA	8.24	11.42	11.38	8.51	8.03
Current ratio	2.26	2.14	1.73	0.73	0.69
Interest coverage	0	0	0	0	0
Income quality	0.21	0.29	-1.02	-0.67	313.38
Dividend Yield	0	0	0	0	0
Payout ratio	0	0.08	0	0	0
Sales general and administrative to revenue	0.1	0.12	0.13	0.1	0.12
Research and developement to revenue	0.04	0.05	0.04	0.07	0.07
Intangibles to total assets	0.34	0.33	0.33	0.33	0.32
Capex to operating cash flow	-12.17	-5.77	-1.48	-0.38	-0.32
Capex to revenue	-0.21	-0.32	-0.12	-0.09	-0.09
Capex to depreciation	-2.99	-4.34	-1.48	-1.21	-0.92
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	1.41	2.2	1.57	3.11	0.15
ROIC	0.02	0.01	0.02	0.03	0.01
Return on tangible assets	0.02	0.04	-0.02	-0.08	0
Graham Net	-1.4	-1.51	-1.67	-1.64	-1.58
Working capital	1.26B	1.06B	825.9M	-733.75M	-982M
Tangible asset value	1.08B	1.23B	1.27B	972.23M	1.04B
Net current asset value	-1.85B	-2.15B	-2.27B	-2.38B	-2.34B
Invested capital	0.62	0.67	0.71	0.78	0.79
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	38.44	35.89	38.96	31.58	27.2
Days payables outstanding	42.76	34.05	32.71	36.68	34.4
Days of inventory on hand	18.82	28.07	29.62	36.67	33.92
Receivables turnover	2.34	2.51	2.31	2.85	3.31
Payables turnover	2.1	2.64	2.75	2.45	2.62
Inventory turnover	4.78	3.21	3.04	2.45	2.65
ROE	0.02	0.05	-0.02	-0.12	0
Capex per share	-0.12	-0.18	-0.08	-0.06	-0.05

1873.HK Frequently Asked Questions

What is Viva Biotech Holdings stock symbol ?

Viva Biotech Holdings is a CN stock and trading under the symbol 1873.HK

What is Viva Biotech Holdings stock quote today ?

Viva Biotech Holdings stock price is $0.415 today.

Is Viva Biotech Holdings stock public?

Yes, Viva Biotech Holdings is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 4.92M
Market Capitalization 1.02B
Employee 2.08K
CEO Dr. Chen Cheney Mao Ph.D.
Headquarters Shanghai,CN
IPO Date 2019-05-09
Website https://www.vivabiotech.com.cn

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.